NCT02862457View on ClinicalTrials.gov

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 23, 2016

Primary Completion Date

November 20, 2020

Study Completion Date

November 20, 2020

Conditions
NeoplasmsCarcinoma, Non-Small-Cell Lung
Interventions
DRUG

Epacadostat 25 mg

Oral administration

DRUG

Epacadostat 100 mg

Oral administration

BIOLOGICAL

pembrolizumab 200 mg

Intravenous (IV) infusion

DRUG

Cisplatin 75 mg/m^2

IV infusion

DRUG

Carboplatin Area Under the Curve (AUC) 5

IV infusion

DRUG

Pemetrexed 500 mg/m^2

IV infusion

DRUG

Paclitaxel 200 mg/m^2

IV infusion

DRUG

Carboplatin AUC 6

IV infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02862457 - Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) | Biotech Hunter | Biotech Hunter